Qiagen has obtained CE mark for its QuantiFeron SARS-CoV-2 assay, which can assess T-cell responses to Covid-19.

Developed using the company’s QuantiFERON interferon gamma release technology, the SARS-CoV-2 assay is designed to detect interferon-γ (IFN-γ) produced by CD4+ and CD8+ T cells in response to a SARS-CoV-2 peptide cocktail in the blood.

The new in vitro diagnostic test has the ability to detect T-cell responses to Covid-19 early in the course of infection or after vaccination.

Qiagen noted that serology tests that measure antibodies in people after vaccination, often generate positive test results but cannot assess cellular responses.

T-cell detection can provide vital insights into the immune response to a SARS-CoV-2 infection in individuals, which is beyond serology alone.

The new CE mark-granted test from Qiagen can also assess cell-mediated immunity in individuals who have been vaccinated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Qiagen molecular diagnostics business area head and senior vice-president Jean-Pascal Viola said: “T-cells provide valuable insights into our immune system’s response to Covid-19.

“The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us.”

The company stated that T-cell response to the virus decreases slowly when compared to the antibody response.

The response helps to indicate how severe the illness triggered by SARS-CoV-2 will be in Covid-19 patients.

It also helps to find the immunity levels in recovered patients.

Furthermore, the new QuantiFERON SARS-CoV-2 assay should be used in combination with other laboratory testing and epidemiological/clinical evaluation.

Recently, the company’s Liaison QuantiFeron-TB Gold Plus assay received approval from the US Food and Drug Administration (FDA) for use on DiaSorin‘s Liaison XS platform.